1

Viracta Therapeutics

#10530

Rank

$317.95K

Marketcap

US United States

Country

Viracta Therapeutics
Leadership team

Mr. Daniel R. Chevallard (CFO, COO & Sec.)

Dr. Lisa Rojkjaer (Chief Medical Officer)

Mr. Mark Andrew Rothera (CEO, Pres & Director)

Products/ Services
Biopharma, Biotechnology, Medical, Pharmaceutical, Therapeutics
Headquarters
Cardiff By The Sea, California, United States
Established
2007
Company Registration
SEC CIK number: 0001061027
Traded as
VIRX
Social Media
Overview
Location
Summary
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510 (formerly SNS-510), a preclinical-stage PDK-1 inhibitor. It is evaluating development and collaboration opportunities for vecabrutinib in combination with chimeric antigen receptor T-cell therapies and VRx-510 in various oncology indications. The company was formerly known as Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. in February 25, 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.
History

Viracta Therapeutics was founded in 2019 to develop novel treatments for RNA viruses associated with multiple disease areas. The company is rapidly advancing its drug development program by leveraging its proprietary technologies to design small molecules that modulate RNA virus replication and translation.

Mission
To be a leader in the development of innovative medicines for the prevention and treatment of viral diseases.
Vision
To develop treatments that help improve the lives of patients who suffer from viral diseases.
Key Team

Dr. Susan Perrine M.D. (Scientific Founder and Consultant)

Dr. Robert M. Williams Ph.D. (Co-Founder)

Dr. Ronald J. Berenson M.D. (Co-Founder and Consultant)

Dr. Douglas V. Faller M.D., Ph.D. (Scientific Founder & Chairman of Scientific Advisory Board)

Mr. George Hillman (Co-Founder)

Dr. Thalia Papayannopoulou M.D. (Co-Founder)

Dr. Ayman El-Guindy (Chief Scientific Officer)

Recognition and Awards
Viracta Therapeutics has been recognized as “2018 Newcomer of the Year” by the Massachusetts Biotechnology Council, as well as a “Fast-Growing Business of the Year” recipient from the San Diego Business Journal.
References

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Viracta Therapeutics
Leadership team

Mr. Daniel R. Chevallard (CFO, COO & Sec.)

Dr. Lisa Rojkjaer (Chief Medical Officer)

Mr. Mark Andrew Rothera (CEO, Pres & Director)

Products/ Services
Biopharma, Biotechnology, Medical, Pharmaceutical, Therapeutics
Headquarters
Cardiff By The Sea, California, United States
Established
2007
Company Registration
SEC CIK number: 0001061027
Traded as
VIRX
Social Media